ARPA-H Launches Two New Programs
EMBODY: Engineering of Immune Cells Inside the Body
The goal of EMBODY is to radically alter how immune therapies are developed and delivered for life-threatening and chronic conditions by retraining healthy immune cells, and eliminating time, cost and access hurdles.
“By developing agents that target specific immune cell types, essentially providing instructions to cells already active inside your body, we hope to make advanced immunotherapies available close to home for Americans across the country,” said EMBODY Program Manager Daria Fedyukina, Ph.D., in ARPA-H’s recent program announcement.
PRINT (Personalized Regenerative Immunocompetent Nanotechnology Tissue)
PRINT intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on organs that will not require immunosuppressive drugs.
“By starting from multiple different types of cells, we will be creating organs that will be individually matched,” said PRINT Program Manager Ryan Spitler, Ph.D., in ARPA-H’s recent program announcement. “The body will not recognize it as a foreign entity, eliminating the need of immunosuppressive drugs, which has never been done in the history of organ transplantation.”
To learn more about both programs, including how to register for the upcoming Proposers’ Days, visit the EMBODY program page and PRINT program page
- AMYRA Successfully Demonstrates a New Therapeutic Paradigm – GlobeNewswire
… Immunology – Nutritional Immunology (https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1425982/full). AMYNOPEP is the … - American Lung Association invites applications for Allergic Respiratory Diseases Research Award
… Research Award. Grants of up to $150000 over two years will be awarded in support of research in academic allergy and immunology divisions…. - Trudeau Institute honors Ralph Steinman at lecture | News, Sports, Jobs
SARANAC LAKE — The Trudeau Institute continues its tradition of advancing immunological research by hosting the annual Ralph M. Steinman Memorial … - GSK, Cambridge to Partner on R&D for Kidney and Respiratory Diseases – PharmTech
The Cambridge-GSK Translational Immunology Collaboration builds on an existing scientific relationship between the biopharma company and the … - GSK and Cambridge scientists join forces in $65M immune R&D deal – Fierce Biotech
Called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), the partnership will build on GSK and Cambridge's existing relationship …